European Union - English - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drugs used in diabetes - diabetes mellitus where treatment with insulin is required. insulin human winthrop rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxaliplatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxaliplatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - sevelamer carbonate - hyperphosphatemia; renal dialysis - all other therapeutic products - sevelamer carbonate winthrop is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.sevelamer carbonate winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/l.sevelamer carbonate winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; hydrogenated castor oil; carnauba wax; stearic acid; colloidal anhydrous silica; microcrystalline cellulose; macrogol 6000; mannitol; maize starch; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - clopidogrel winthrop plus aspirin is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel winthrop plus aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel winthrop plus aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: erythrosine; gelatin; indigo carmine; iron oxide black; titanium dioxide; pregelatinised maize starch - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; hypromellose; pregelatinised maize starch; microcrystalline cellulose; sodium stearylfumarate - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.